The Kidney Disease: Improving Global Outcomes (KDIGO) organization has released new guidelines for management of diabetes in chronic kidney disease. These guidelines take a multidisciplinary approach. Below are a few medication highlights of the 12 recommendations as well as a link with all of the recommendations.
- Treatment with an angiotension-converting enzyme inhibitor (ACEI) or angiotension II receptor blocker (ARB) to be initiated in person with diabetes, hypertension and albuminuria, and titrate to highest approved dose that is tolerated.
- Advising persons with diabetes who use tobacco to quit using tobacco products.
- Treating persons with type 2 diabetes, CKD and eGFR >/= 30 mL/min/1.73 m2 with metformin.
- Treating persons with type 2 diabetes, CKD and eGFR >/= 30 mL/min/1.73 m2 with SGLT2-inhibitor.
- In persons with type 2 diabetes and CKD who have not achieve their goal glycemic targets on metformin and SGLT2-inhibitor or are unable to tolerate these medications, a long acting GLP-1 receptor agonist is recommended.
Please share your thoughts and subscribe to receive my blogs.
#diabetes #kidney #medications
Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.